The Medical Advisor

Introduction: The Obesity Drug Revolution Is Entering a New Phase Obesity treatment is undergoing a major transformation. Over the past decade, therapies targeting incretin hormones have reshaped clinical practice, but the next five years (2026–2030) are expected to redefine obesity medicine entirely. The field is evolving from single-hormone appetite suppression to multi-hormonal metabolic reprogramming , combining appetite control, energy expenditure, satiety signaling, and body composition regulation. This article provides a structured, evidence-based overview of the most important obesity drugs in development and clinical use, including GLP-1 receptor agonists, dual and triple agonists, amylin analogs, and emerging combination therapies. 1. The Current Standard (2024–2026): GLP-1 and Dual Incretin Therapies The foundation of modern obesity pharmacotherapy is built on incretin-based drugs. GLP-1 Receptor Agonists The most widely used drug in this category is semaglutide , a glucagon...

At a glance Some natural alternatives to Ozempic include berberine, which may help manage blood sugar and support weight loss, along with high-protein diets, fiber-rich foods, and drinking water before meals to help control appetite. However, these options are generally not as potent or predictable as prescription medications like Ozempic, so they should not be viewed as direct substitutes for medical therapy. There are natural alternatives to Ozempic like berberine, turmeric and psyllium husk. Ozempic is a popular weight-loss medication that helps curb appetite and induces various metabolic changes linked to improved weight management. However, this injectable medication is costly, and its long-term use may lead to serious health issues, including thyroid cancer, muscle mass loss, and kidney damage. The  2023 report  from the World Obesity Federation estimates that the economic impact of overweight and obesity will surpass $4.3 trillion annually by...

Introduction What is the "Stanford Fenbendazole Protocol"? I bet you've never heard of the "Stanford Fenbendazole Protocol" for treating Cancer. Yet, it exists. But it's heavily suppressed by search engines and mainstream Oncology, especially in the United States and Canada. In 2021 a group at Stanford University Medical Center, Department of Medicine, published a peer-reviewed Case Series (Clin. Oncol. Case Rep 2021)* on a "forbidden" repurposed drug, Fenbendazole. *Note: Clinical Oncology Case Reports is a peer-reviewed International clinical and medical oncology and cancer research Journal. Clinical Oncology Case Reports (COCR) is a high-impact multidisciplinary journal focus on the area of clinical and medical investigation. They wrote about 3 cases of Stage 4 Cancer patients who self-treated and cured their cancers.   Case 1: 63 year old man with a Stage 4 Renal Cell Carcinoma (clear cell) , a 5.3cm mass and mets to pancreas and bone, fail...